COMP <GO>
MIRM vs GRFS // EV/EBITDA & P/E VALUATION
Mirum Pharmaceuticals Inc. (NASDAQ) VS. Grifols S.A. (NASDAQ) • 15-METRIC TALLY: MIRM 0
— GRFS 2
■ METRIC PARITY
LAST: $85.74 (+0.87%) • MKT CAP: $5.52B
valuation
—
LAST: $8.51 (+5.06%) • MKT CAP: $5.57B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. GRFS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | GRFS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -4.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -4.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 66.8 | -18.40 | GRFS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.52B | $5.57B | -$50.0M | GRFS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | GRFS REV | MIRM GROSS % | GRFS GROSS % | MIRM FCF | GRFS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | — | — | — | $54.9M | — |
| FY 2024 | $336.9M | — | — | — | $9.3M | — |
| FY 2023 | $186.4M | — | — | — | -$79.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
GRFS // BETA —